Drug
Imagabalin clinical trials
Also written PD 0332334.
- studies test it
- 12
- open now
- 0
- in phase 3
- 6
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2008 (6)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 1
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses imagabalin is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy SubjectsWithdrawnPhase 1PfizerNCT00820794Written as PD 0332334
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)WithdrawnPhase 3PfizerNCT00738738Written as PD-0332334
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety DisorderCompletedPhase 3PfizerNCT00542685Written as PD 0332334
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)TerminatedPhase 3PfizerNCT00735267Written as PD 0332334
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)TerminatedPhase 3PfizerNCT00658762Written as PD 0332334
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)TerminatedPhase 3PfizerNCT00658372Written as PD 0332334
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)TerminatedPhase 3PfizerNCT00658008Written as PD 0332334
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety DisorderCompletedPhase 2PfizerNCT00921063Written as PD 0332334
- A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular HemodialysisCompletedPhase 1PfizerNCT00730145Written as PD-0332334
- An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male VolunteersCompletedPhase 1PfizerNCT00537615Written as PD 0332334
- A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.TerminatedPhase 1PfizerNCT00721422Written as PD 0332334
- Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same TimeTerminatedPhase 1PfizerNCT00809536Written as PD 0332334
Given in every arm · 1 — imagabalin is usual care beside what is tested
Codes
What other systems call imagabalin · ClinicalTrials.gg INT006357
- MeSH (NLM) C583768imagabalinOne source NLM
- UNII (FDA) NDG6931B7HIMAGABALINConfirmed FDA, NLM, Wikidata
- Wikidata Q6002030imagabalinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83785ImagabalinOne source FDA
- DrugBank DB12105One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583768 | imagabalin | One source NLM |
| UNII (FDA) | NDG6931B7H | IMAGABALIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6002030 | imagabalin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83785 | Imagabalin | One source FDA |
| DrugBank | DB12105 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.